Shopping Cart 0
Cart Subtotal
USD 0

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Review, H1 2018

Summary

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

The latest report Glycogen Synthase Kinase 3 Beta-Pipeline Review, H1 2018, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules.

It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex.

It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Alzheimer's Disease, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Lung Cancer, Breast Cancer, Cognitive Impairment, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lymphoma, Menkes Disease (Kinky Hair Disease), Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Ovarian Cancer, Retinitis Pigmentosa (Retinitis) and Tauopathies.

Furthermore, this report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Overview

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Companies Involved in Therapeutics Development

Actuate Therapeutics Inc

AMO Pharma Ltd

Angelini Group

Jeil Pharmaceutical Co Ltd

Mitsubishi Tanabe Pharma Corp

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Drug Profiles

9-ING41-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit GSK3-Beta for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-AD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JGK-263-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

manzamine A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK3B for Ovarian Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for CNS Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK3B for Amyotropic Lateral Sclerosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GSK3B for Cardiovascular, Central Nervous System and Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tideglusib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Dormant Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Discontinued Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Product Development Milestones

Featured News & Press Releases

Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type

Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers

Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

Oct 18, 2017: AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy

May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy

Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research

Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy

Mar 29, 2016: FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma

Dec 18, 2015: Actuate Therapeutics Provides Update On 9-ING

Nov 19, 2015: Actuate Therapeutics Presents Data On 9-ING41 at the Society of Neuro Oncology meeting

Apr 20, 2015: Actuate Therapeutics Provides Update On GSK-3B at the AACR Meeting

Dec 03, 2012: Alzheimer's researcher reveals a protein's dual destructiveness-and therapeutic potential

Jul 20, 2012: Noscira Presents Phase II Results Of tideglusib At Alzheimer's Association International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Top 10 Indications, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H1


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Indication, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2018 (Contd..1), H1

Number of Products under Investigation by Universities/Institutes, H1

Products under Investigation by Universities/Institutes, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pipeline by Actuate Therapeutics Inc, H1

Pipeline by AMO Pharma Ltd, H1

Pipeline by Angelini Group, H1

Pipeline by Jeil Pharmaceutical Co Ltd, H1

Pipeline by Mitsubishi Tanabe Pharma Corp, H1

Dormant Products, H1

Dormant Products, H1 2018 (Contd..1), H1

Discontinued Products, H1

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Actuate Therapeutics Inc

AMO Pharma Ltd

Angelini Group

Jeil Pharmaceutical Co Ltd

Mitsubishi Tanabe Pharma Corp

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Pipeline Review, H1 2018

Summary

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

The latest report Glycogen Synthase Kinase 3 Beta-Pipeline Review, H1 2018, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules.

It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex.

It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Alzheimer's Disease, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Lung Cancer, Breast Cancer, Cognitive Impairment, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lymphoma, Menkes Disease (Kinky Hair Disease), Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Ovarian Cancer, Retinitis Pigmentosa (Retinitis) and Tauopathies.

Furthermore, this report also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Overview

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Companies Involved in Therapeutics Development

Actuate Therapeutics Inc

AMO Pharma Ltd

Angelini Group

Jeil Pharmaceutical Co Ltd

Mitsubishi Tanabe Pharma Corp

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Drug Profiles

9-ING41-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit GSK3-Beta for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-AD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JGK-263-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

manzamine A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GSK3B for Ovarian Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK-3 Beta for CNS Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GSK3B for Amyotropic Lateral Sclerosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GSK3B and Nrf2 for Alzheimer's Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GSK3B for Cardiovascular, Central Nervous System and Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tideglusib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Dormant Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Discontinued Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)-Product Development Milestones

Featured News & Press Releases

Mar 15, 2018: AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type

Feb 15, 2018: Actuate Therapeutics Announces FDA Acceptance Of IND Application For 9-ING-41 And Clearance To Proceed With Clinical Study In Patients With Advanced Cancers

Oct 26, 2017: Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

Oct 18, 2017: AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting

Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study

Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy

May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy

Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research

Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy

Mar 29, 2016: FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma

Dec 18, 2015: Actuate Therapeutics Provides Update On 9-ING

Nov 19, 2015: Actuate Therapeutics Presents Data On 9-ING41 at the Society of Neuro Oncology meeting

Apr 20, 2015: Actuate Therapeutics Provides Update On GSK-3B at the AACR Meeting

Dec 03, 2012: Alzheimer's researcher reveals a protein's dual destructiveness-and therapeutic potential

Jul 20, 2012: Noscira Presents Phase II Results Of tideglusib At Alzheimer's Association International Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Top 10 Indications, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H1


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Indication, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2018 (Contd..1), H1

Number of Products under Investigation by Universities/Institutes, H1

Products under Investigation by Universities/Institutes, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pipeline by Actuate Therapeutics Inc, H1

Pipeline by AMO Pharma Ltd, H1

Pipeline by Angelini Group, H1

Pipeline by Jeil Pharmaceutical Co Ltd, H1

Pipeline by Mitsubishi Tanabe Pharma Corp, H1

Dormant Products, H1

Dormant Products, H1 2018 (Contd..1), H1

Discontinued Products, H1

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Actuate Therapeutics Inc

AMO Pharma Ltd

Angelini Group

Jeil Pharmaceutical Co Ltd

Mitsubishi Tanabe Pharma Corp

chat_bubbleLet's Chat